Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells - PubMed

Affiliations

• PMID: 21448567
• DOI: 10.1007/s00210-011-0623-0

Comparative Study

Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells

Tatiane C Izidoro-Toledo et al. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun.

Abstract

Statins exert anti-inflammatory effects and downregulate matrix metalloproteinases (MMPs) expression, thus contributing to restore cardiovascular homeostasis in cardiovascular diseases. We aimed at comparing the effects of different statins (simvastatin, atorvastatin, and pravastatin) on MMP-2, MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1, TIMP-2, and MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios released by human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA). HUVECs were incubated with statins (0.1-10 μM) for 12 h before stimulation with PMA 100 nM. Monolayers were used to perform cell viability assays and the supernatants were collected to determine MMPs and TIMPs levels by gelatin zymography and/or enzyme immunoassay. While treatment with PMA increased MMP-9 and TIMP-1 levels (by 556% and 159%, respectively; both P < 0.05), it exerted no effects on MMP-2 and TIMP-2 levels. Simvastatin and atorvastatin, but not pravastatin, attenuated PMA-induced increases in MMP-9 levels (P < 0.05). Only atorvastatin decreased baseline MMP-2 levels significantly (P < 0.05). We found no effects on TIMP-2 levels. Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Our data support the notion that statins with different physicochemical features exert variable effects on MMP/TIMP ratios (which reflect net MMP activity). Our results suggest that more lipophilic statins (simvastatin and atorvastatin), but not the hydrophilic statin pravastatin, downregulate net MMP-9 activity. However, atorvastatin and pravastatin may downregulate net MMP-2 activity. The clinical implications of the present findings deserve further investigation.

Similar articles

• The effects of high glucose and atorvastatin on endothelial cell matrix production.

  McGinn S, Poronnik P, Gallery ED, Pollock CA. McGinn S, et al. Diabet Med. 2004 Oct;21(10):1102-7. doi: 10.1111/j.1464-5491.2004.01293.x. Diabet Med. 2004. PMID: 15384957

• Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.

  Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, De Caterina R. Massaro M, et al. Cardiovasc Res. 2010 May 1;86(2):311-20. doi: 10.1093/cvr/cvp375. Epub 2009 Nov 27. Cardiovasc Res. 2010. PMID: 19946014

• Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.

  Lee DK, Park EJ, Kim EK, Jin J, Kim JS, Shin IJ, Kim BY, Lee H, Kim DE. Lee DK, et al. Cell Physiol Biochem. 2012;30(3):499-511. doi: 10.1159/000341433. Epub 2012 Jul 19. Cell Physiol Biochem. 2012. PMID: 22814256

• Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.

  Zhou Z, Rahme E, Pilote L. Zhou Z, et al. Am Heart J. 2006 Feb;151(2):273-81. doi: 10.1016/j.ahj.2005.04.003. Am Heart J. 2006. PMID: 16442888 Review.

• Comparison of statins in hypertriglyceridemia.

  Stein EA, Lane M, Laskarzewski P. Stein EA, et al. Am J Cardiol. 1998 Feb 26;81(4A):66B-69B. doi: 10.1016/s0002-9149(98)00041-1. Am J Cardiol. 1998. PMID: 9526817 Review.

Cited by

• Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin.

  Tremoulet AH, Jain S, Burns JC. Tremoulet AH, et al. Expert Opin Orphan Drugs. 2015;3(9):967-970. doi: 10.1517/21678707.2015.1066246. Epub 2015 Jul 13. Expert Opin Orphan Drugs. 2015. PMID: 27525197 Free PMC article.

• Associations of markers of inflammation and coagulation with delirium during critical illness.

  Girard TD, Ware LB, Bernard GR, Pandharipande PP, Thompson JL, Shintani AK, Jackson JC, Dittus RS, Ely EW. Girard TD, et al. Intensive Care Med. 2012 Dec;38(12):1965-73. doi: 10.1007/s00134-012-2678-x. Epub 2012 Aug 18. Intensive Care Med. 2012. PMID: 22903241 Free PMC article.

• Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

  Sabbatini AR, Barbaro NR, de Faria AP, Modolo R, Ritter AM, Pinho C, Amorim RF, Fontana V, Moreno H. Sabbatini AR, et al. J Clin Hypertens (Greenwich). 2016 Oct;18(10):969-975. doi: 10.1111/jch.12865. Epub 2016 Jul 14. J Clin Hypertens (Greenwich). 2016. PMID: 27412873 Free PMC article.

• Simvastatin pretreatment ameliorates t-PA-induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats.

  Yin B, Li DD, Xu SY, Huang H, Lin J, Sheng HS, Fang JH, Song JN, Zhang M. Yin B, et al. Neuropsychiatr Dis Treat. 2019 Jul 16;15:1993-2002. doi: 10.2147/NDT.S199371. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31410004 Free PMC article.

• Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

  Tremoulet AH, Jain S, Jone PN, Best BM, Duxbury EH, Franco A, Printz B, Dominguez SR, Heizer H, Anderson MS, Glodé MP, He F, Padilla RL, Shimizu C, Bainto E, Pancheri J, Cohen HJ, Whitin JC, Burns JC. Tremoulet AH, et al. J Pediatr. 2019 Dec;215:107-117.e12. doi: 10.1016/j.jpeds.2019.07.064. Epub 2019 Sep 24. J Pediatr. 2019. PMID: 31561960 Free PMC article. Clinical Trial.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal